阿奇霉素治疗小儿支原体肺炎的临床效果观察(1)
[摘要]目的 探讨阿奇霉素治疗31例小儿支原体肺炎的临床效果。方法 选取2014年6月～2017年6月我院收治的小儿支原体肺炎患者62例，随机分为对照组(n=31)和观察组(n=31)。两组均给予对症治疗，在此基础上，对照组再给予红霉素治疗，观察组则给予阿奇霉素治疗。比较两组的发热时间、咳嗽时间、啰音持续时间、治疗总有效率和不良反应发生率等指标。结果 ①观察组发热时间、咳嗽时间和啰音持续时间均短于对照组(P<0.05)。②观察组治疗总有效率为94.5%，显著高于对照组(70.9%)(P<0.05)。③观察组不良反应发生率为12.9%，显著低于对照组(35.4%)，差异均有统计学意义(P<0.05)。结论 对小儿支原体肺炎的治疗，阿奇霉素可有效改善患儿的临床症状、体征，治疗效果好，不良反应少，是一种理想的治疗药物。
[关键词]小儿支原体肺炎；阿奇霉素；红霉素；临床效果
[中图分类号] R725.6 [文献标识码] A [文章编号] 1674-4721(2018)5(a)-0160-03
[Abstract]Objective To investigate clinical efficacy of Azithromycin in the treatment of 31 cases of Mycoplasma pneumonia in children.Methods A total of 62 children with Mycoplasma pneumonia were collected from June 2014 to June 2017 in our hospital and were randomly divided into control group(n=31) and observation group(n=31).The two groups were given symptomatic treatment.On the basis of treatment，the control group was treated with Erythromycin，while the observation group was treated with Azithromycin.The therapeutic effects of the two groups were compared.Results ①The fever time，cough time and rale time in the observation group were shorter than those in the control group(P<0.05).②The total effective rate of the observation group was 94.5%，which was significantly higher than 70.9% of the control group(P<0.05).③The adverse reaction rate of the observation group was 12.9%，which was significantly lower than 35.4% of the control group，the differences were statistically significant(P<0.05).Conclusion In the treatment of children with Mycoplasma pneumonia，Azithromycin can effectively improve the patient′s clinical symptoms and signs，treatment effect is good，and adverse reaction is less.It is an ideal treatment drug.
[Key words]Mycoplasma pneumonia in children；Azithromycin；Erythromycin；Clinical efficacy
近年來，儿科是医院科室最繁忙的科室，主要是由于二孩政策的实施，小儿的出生率明显增加；儿科医生数量不足，无法满足科室需求；小儿稍有不适，就到医院就诊，增加了医院的压力；小儿的免疫力相对降低，易出现病痛，常到医院就诊。肺炎支原体(Mycoplasma pneumoniae，MP)是一种常见的小儿肺炎病原体，可通过飞沫方式传染，潜伏期约2～3周[1-5]，当小儿感染MP后，容易引发支原体肺炎，临床上主要表现是喘息、低热、剧烈咳嗽，该种肺炎占1%～30%[6-8]，近年来支原体肺炎发病率持续升高，已成为小儿呼吸道疾病的主要病因。对小儿支原体肺炎的治疗，不同的治疗，效果不一，为进一步寻找更合适的治疗药物及方案，本研究探讨阿奇霉素在小儿支原体肺炎中的治疗效果，现报道如下。
1资料与方法
1.1一般资料
选取2014年6月～2017年6月我院收治的小儿支原体肺炎患者62例，随机分为对照组(n=31)和观察组(n=31)。对照组男17例，女14例；年龄2.5～9.8岁，平均(6.2±1.2)岁；病程1～3周，平均(1.2±0.4)周。观察组男16例，女15例；年龄2.2～10.0岁，平均(6.3±1.1)岁；病程1～3周，平均(1.2±0.3)周。两组患儿的一般资料比较，差异无统计学意义(P>0.05)，具有可比性。本研究经我院医学伦理委员会审批。
1.2入组标准
①符合小儿支原体肺炎的诊断标准[9]；②血液检验为肺炎支原体抗体阳性；③家长知情并同意本研究。
1.3排除标准, 百拇医药(欧齐)
[关键词]小儿支原体肺炎；阿奇霉素；红霉素；临床效果
[中图分类号] R725.6 [文献标识码] A [文章编号] 1674-4721(2018)5(a)-0160-03
[Abstract]Objective To investigate clinical efficacy of Azithromycin in the treatment of 31 cases of Mycoplasma pneumonia in children.Methods A total of 62 children with Mycoplasma pneumonia were collected from June 2014 to June 2017 in our hospital and were randomly divided into control group(n=31) and observation group(n=31).The two groups were given symptomatic treatment.On the basis of treatment，the control group was treated with Erythromycin，while the observation group was treated with Azithromycin.The therapeutic effects of the two groups were compared.Results ①The fever time，cough time and rale time in the observation group were shorter than those in the control group(P<0.05).②The total effective rate of the observation group was 94.5%，which was significantly higher than 70.9% of the control group(P<0.05).③The adverse reaction rate of the observation group was 12.9%，which was significantly lower than 35.4% of the control group，the differences were statistically significant(P<0.05).Conclusion In the treatment of children with Mycoplasma pneumonia，Azithromycin can effectively improve the patient′s clinical symptoms and signs，treatment effect is good，and adverse reaction is less.It is an ideal treatment drug.
[Key words]Mycoplasma pneumonia in children；Azithromycin；Erythromycin；Clinical efficacy
近年來，儿科是医院科室最繁忙的科室，主要是由于二孩政策的实施，小儿的出生率明显增加；儿科医生数量不足，无法满足科室需求；小儿稍有不适，就到医院就诊，增加了医院的压力；小儿的免疫力相对降低，易出现病痛，常到医院就诊。肺炎支原体(Mycoplasma pneumoniae，MP)是一种常见的小儿肺炎病原体，可通过飞沫方式传染，潜伏期约2～3周[1-5]，当小儿感染MP后，容易引发支原体肺炎，临床上主要表现是喘息、低热、剧烈咳嗽，该种肺炎占1%～30%[6-8]，近年来支原体肺炎发病率持续升高，已成为小儿呼吸道疾病的主要病因。对小儿支原体肺炎的治疗，不同的治疗，效果不一，为进一步寻找更合适的治疗药物及方案，本研究探讨阿奇霉素在小儿支原体肺炎中的治疗效果，现报道如下。
1资料与方法
1.1一般资料
选取2014年6月～2017年6月我院收治的小儿支原体肺炎患者62例，随机分为对照组(n=31)和观察组(n=31)。对照组男17例，女14例；年龄2.5～9.8岁，平均(6.2±1.2)岁；病程1～3周，平均(1.2±0.4)周。观察组男16例，女15例；年龄2.2～10.0岁，平均(6.3±1.1)岁；病程1～3周，平均(1.2±0.3)周。两组患儿的一般资料比较，差异无统计学意义(P>0.05)，具有可比性。本研究经我院医学伦理委员会审批。
1.2入组标准
①符合小儿支原体肺炎的诊断标准[9]；②血液检验为肺炎支原体抗体阳性；③家长知情并同意本研究。
1.3排除标准, 百拇医药(欧齐)
参见：首页 > 医疗版 > 疾病专题 > 呼吸内科 > 肺炎 > 支原体肺炎